Merck & Company, Inc. found using ticker (MRK) now have 24 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 135 and 96 with a mean TP of 119.25. Now with the previous closing price of 108.28 this now indicates there is a potential upside of 10.1%. There is a 50 day moving average of 108.9 while the 200 day moving average is 97.92. The company has a market capitalisation of $273,152m. Visit the company website at: https://www.merck.com
The potential market cap would be $300,826m based on the market concensus.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
